Table of Contents

SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C. 20549

---

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

 

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 2, 2003

 

 

RESPIRONICS, INC.

---

 

(Exact name of Registrant as specified in its charter)

 

 

Delaware		000-16723		25-1304989
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)
1010 Murry Ridge Lane Murrysville, Pennsylvania				15668-8525
(Address of Principal Executive Offices)				(Zip Code)

 

 

724-387-5200

(Registrant’s telephone number, including area code)

---

Table of Contents

TABLE OF CONTENTS

 

		Page
Item 9. REGULATION FD DISCLOSURE		2
SIGNATURES		3
INDEX TO EXHIBITS		4

---

Table of Contents

Item 9. REGULATION FD DISCLOSURE.

 

The following information is furnished pursuant to Item 12, “Disclosure of Results of Operations and Financial Condition.”

 

On October 2, 2003, Respironics, Inc. issued a press release announcing that John L. Miclot has been appointed President and Chief Executive Officer of the Company. In that press release, Respironics, Inc. also reported that it expects to report earnings for the first quarter of fiscal year 2004 in line with its previous guidance. A copy of the press release is attached hereto as Exhibit 99.

 

Exhibits

 

99         Press release, dated October 2, 2003, issued by Respironics, Inc.

 

2

---

Table of Contents

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Dated: October 2, 2003

 

3

---

Table of Contents

INDEX TO EXHIBITS

 

Exhibit No.		Description
99		Press release, dated October 2, 2003, issued by Respironics, Inc.

 

4